Aydah AlAwadhi, Consultant Medical Oncologist and Division Chair of Hematology and Oncology Department at Sheikh Shakbout Medical City, Abu Dhabi, shared a post on LinkedIn:
“Excellent weekend read – a comprehensive review exploring the rapidly evolving landscape of antibody-drug conjugates (ADCs) and their growing impact on precision oncology.
ADCs have evolved far beyond the concept of “targeted chemotherapy.”
They are now becoming one of the most sophisticated platforms in precision oncology.
What is shaping the next era of ADC development?
- Smarter linker technology
- More potent and novel payloads
- Better biomarker-driven patient selection
- Rational combination strategies
- Deeper understanding of resistance biology
Perhaps one of the most exciting shifts is how ADCs are expanding biomarker boundaries, particularly with HER2-low and HER2-ultralow breast cancer, Trop-2 expression, and folate receptor alpha (FRα)-targeted therapies in ovarian cancer.
The future may not be about developing more ADCs alone, but rather delivering:
- The right payload
- To the right target
- In the right biology
- For the right patient
Exciting era in precision oncology.”
Other articles featuring Aydah AlAwadhi on OncoDailty.
